Yasuda et al. used expression cloning to identify osteoclast differentiation factor (ODF) — the membrane-bound signal on osteoblasts that instructs osteoclast progenitors to differentiate. The study asks: what is the molecular identity of the cell-contact signal driving osteoclastogenesis, and how does OPG inhibit it? ODF was found to be identical to TRANCE/RANKL, establishing the OPG/RANKL/RANK pathway as the master regulator of bone resorption.
The OPG/RANKL/RANK axis is the single most important molecular pathway in bone remodeling — and this is the paper that identified it. When you give denosumab to a patient with osteoporosis, bone metastases, or giant cell tumor of bone, you are administering a monoclonal antibody that mimics OPG: it binds RANKL and prevents osteoclast differentiation, exactly as shown here.
This axis also explains why inflammatory conditions (rheumatoid arthritis, multiple myeloma, hyperparathyroidism) cause bone loss: activated T cells and inflammatory cytokines upregulate RANKL expression through the same three signaling pathways (vitamin D receptor, PKA, gp130) identified in this paper.
For boards: know that OPG is a soluble decoy receptor (not a membrane protein), that RANKL is expressed on osteoblasts/stromal cells (not osteoclasts), and that M-CSF is required alongside RANKL for osteoclast differentiation.
The shared monocyte/macrophage lineage of osteoclasts and dendritic cells. Both regulated by RANKL/RANK. Is why immune activation and bone resorption are so tightly coupled in inflammatory disease.
Yasuda et al. used expression cloning to identify osteoclast differentiation factor (ODF) — the membrane-bound signal on osteoblasts that instructs osteoclast progenitors to differentiate. The study asks: what is the molecular identity of the cell-contact signal driving osteoclastogenesis, and how does OPG inhibit it? ODF was found to be identical to TRANCE/RANKL, establishing the OPG/RANKL/RANK pathway as the master regulator of bone resorption.
The OPG/RANKL/RANK axis is the single most important molecular pathway in bone remodeling — and this is the paper that identified it. When you give denosumab to a patient with osteoporosis, bone metastases, or giant cell tumor of bone, you are administering a monoclonal antibody that mimics OPG: it binds RANKL and prevents osteoclast differentiation, exactly as shown here.
This axis also explains why inflammatory conditions (rheumatoid arthritis, multiple myeloma, hyperparathyroidism) cause bone loss: activated T cells and inflammatory cytokines upregulate RANKL expression through the same three signaling pathways (vitamin D receptor, PKA, gp130) identified in this paper.
For boards: know that OPG is a soluble decoy receptor (not a membrane protein), that RANKL is expressed on osteoblasts/stromal cells (not osteoclasts), and that M-CSF is required alongside RANKL for osteoclast differentiation.
The shared monocyte/macrophage lineage of osteoclasts and dendritic cells. Both regulated by RANKL/RANK. Is why immune activation and bone resorption are so tightly coupled in inflammatory disease.